Articles tagged with Cardiomyocytes
Researchers found that slow release of TT-10 from nanoparticles improved heart function after a heart attack, accompanied by increased cardiomyocyte proliferation and smaller infarct size. The study suggests that PLGA nanoparticles could be used to improve treatment administration efficiency for cardiovascular drugs.
A recent study published at Masonic Medical Research Institute found that electrocution-induced physiological stress can lead to overlapping cardiac conditions in individuals. The research used human induced pluripotent stem cells to investigate the mechanisms behind these conditions, shedding light on potential new treatments.
The study found that the Wntless (Wls) gene plays a critical role in heart regeneration in mice by facilitating signal molecule secretion from cardiomyocytes to cardiac fibroblasts. This promotes heart functional recovery by suppressing CF activation and reducing scar formation.
Researchers at Masonic Medical Research Institute are using human induced pluripotent stem cells (hiPSCs) to create scientific models for studying cardiac arrhythmias and testing therapeutics. The integration of mathematical modeling tools enables the prediction of drug efficacy with minimal adverse effects.
A preclinical study found that age-related decline in two sirtuin enzymes alters mitochondrial dynamics, weakening cardiac contractions in response to ischemia-reperfusion injury. Boosting SIRT1/SIRT3 levels may help protect against such injuries, potentially reducing heart attack complications and deaths.
A new imaging technique developed by the Skala Lab can predict the efficiency of cardiomyocyte differentiation from human pluripotent stem cells, providing a non-invasive quality control method. The technique uses autofluorescence to measure metabolic activity and has been shown to be accurate in predicting outcome with high consistency.
Researchers developed nanoparticles that absorb near-infrared light, creating heat and inhibiting electrical activity in neurons. The biocompatible and biodegradable nanoparticles offer a potential tool for controlling neuronal activity remotely.
A novel lncRNA, Caren, has been identified as a potential therapeutic target for heart failure. It enhances energy production in cardiomyocytes and inhibits the activation of the ATM protein, which accelerates heart failure severity. Increasing Caren expression may inhibit heart failure progression.
Researchers from the University of Tsukuba have demonstrated the direct conversion of scar tissue cells to heart muscle cells in mice after a heart attack. This breakthrough finding suggests that fibroblasts can be directly reprogrammed into cardiomyocytes, potentially preventing heart failure and death.
Researchers have shown that injecting heart muscle cells derived from human induced pluripotent stem cells that overexpress cyclin D2 can aid heart attack recovery. The treatment stimulates proliferation of existing heart muscle cells and promotes angiogenesis, a development of new blood vessels.
Researchers investigated mitochondrial fission and discovered two types of division: midzone and peripheral. Midzone divisions have textbook machinery, while peripheral divisions are associated with stress and dysfunction. The study sheds light on regulation mechanisms and potential therapeutic targets for human diseases.
Scientists created a shape memory polymer to promote cardiomyocyte alignment and growth, providing a platform to study heart development and disease. The research uses stimuli-responsive biomaterials to mimic the dynamic microenvironment during heart development.
Researchers from the Hubrecht Institute mapped the recovery of the heart after a heart attack, highlighting the importance of cardiomyocyte communication in forming scar tissue. The study provides new insights into the complex process of heart recovery, shedding light on potential therapeutic targets to improve outcomes.
A study published in Cell reveals a previously unknown mechanism for the heart's waste removal, highlighting the critical role of macrophages in maintaining cardiac health. The discovery suggests that cardiac dysfunction may arise from defects in immune cells rather than cardiomyocytes.
Researchers found that genes associated with SARS-CoV-2 entry become more active with age, making heart cells vulnerable to damage. The study suggests that existing medicines can inhibit some of these proteins, and new treatments may be developed to protect the heart.
Researchers developed a non-invasive tracking strategy using CRISPR/Cas9 editing to insert the sodium/iodide symporter gene into iPSCs. This allows long-term monitoring of cardiomyocytes after implantation, paving the way for preclinical and clinical development of cardiac cell therapies.
Researchers found that forcing cardiomyocytes to consume glucose instead of fatty acids extended the window for heart cell regeneration, potentially treating conditions like heart failure.
Researchers have identified HIPK2 as a novel regulator of heart failure progression. The kinase was found to play a critical role in maintaining cardiac function, with its deletion leading to progressive deterioration and apoptosis in heart muscle cells.
A new method has been developed to improve the quality of stem cell-derived cardiomyocytes, which can be used to treat heart attacks. The approach, tested in a mouse heart attack model, doubled the engraftment rate of injected cells, showing promise for repairing damaged heart tissue.
A team of CNIC scientists identified SRSF3 as crucial for proper heart function and found that its loss leads to reduced expression of genes involved in contraction. Further research revealed that SRSF3 controls the alternative processing of mTOR, a major regulator of cell metabolism, which is essential for heart health.
Researchers analyzed RNA sequence data from human stem cells as they developed into cardiomyocytes, identifying hundreds of genes associated with varying expression. These 'shooting star' differences may explain complex diseases like cancer and heart disease.
Researchers found that methylmercury increases cardiac fragility by removing an inhibitory brake on Drp1, a protein involved in mitochondrial fission. Treatment with a polysulfide group-releasing compound reversed this effect, suggesting a possible strategy to mitigate cardiotoxicity.
Researchers at UNC McAllister Heart Institute develop stable platform to reprogram human fibroblast cells into cardiomyocytes, creating high-resolution molecular roadmap. The approach identifies key genetic facilitators and signaling molecules driving cell fate development, offering new insights into human cardiac reprogramming.
Researchers at the University of Tsukuba identify diclofenac as a factor promoting cardiac reprogramming in postnatal and adult fibroblasts, while inhibiting COX-2 and suppressing inflammatory signaling. This finding has important implications for developing new therapies for cardiac regeneration in pediatric and adult patients.
Researchers at Baylor College of Medicine have made a groundbreaking finding that enables the reprogramming of adult cardiomyocytes to promote heart tissue regeneration. By manipulating the genetic mechanisms that prevent cardiomyocyte proliferation, scientists have successfully opened up possibilities for treating heart disease.
Researchers at the University of Tokyo have developed an ultra-soft electronic sensor that can closely monitor beating heart cells without affecting their behavior. This breakthrough device uses a nanomesh sensor to study cardiomyocytes in a more faithful way, paving the way for future embedded medical devices.
Scientists have created a model of the upper chambers of the heart using 3D-engineered human heart tissue, which can serve as a tool for evaluating disease mechanisms and testing new drugs. The tissue is derived from human induced pluripotent stem cells and responds to atrial-selective drugs.
Researchers have identified serum response factor (SRF) as a critical regulator of cardiomyocyte maturation. SRF plays a key role in organizing contractile structures and regulating gene expression, but its level affects cell maturity. The study provides new insights into heart muscle development and regeneration.
Researchers at Stanford University School of Medicine discovered that people with cardiomyopathy have abnormally short telomeres in their heart muscle cells. This finding opens the door to new research and drug discovery, potentially allowing for the identification of individuals at risk for heart failure due to genetic defects.
Researchers found that maintaining high levels of the protein vinculin in fruit flies' hearts reduced the effects of aging and improved their life span, quality of life, and metabolism. Flies bred with higher vinculin levels lived up to nine weeks, compared to six weeks for typical fruit flies.
Researchers at Tampere University used artificial intelligence and machine learning to differentiate between genetic cardiac diseases from healthy cells. The study successfully identified specific features in cardiomyocyte beating behavior, enabling accurate diagnosis.
A new cell therapy has been developed to aid heart recovery without implanting cells, using extracellular vesicles secreted by cardiomyocytes derived from human pluripotent stem cells. The therapy shows promising results in recovering cardiac function and reducing arrhythmias in rat models of myocardial infarction.
Researchers have identified a new therapeutic target, OMA1, which protects cardiomyocytes from death and deterioration in heart function when the heart is under stress. Inhibition of OMA1 prevents heart failure in models of chronic tachycardia, hypertension, and myocardial ischemia with cardiac hypertrophy.
A team of researchers at Michigan Technological University has created 3D substrates that mimic the natural heart environment, enabling cardiomyocytes to mature more quickly and have improved functionality. This breakthrough could lead to more effective treatment options for individuals with heart injuries.
Researchers from MIPT studied a nanofibrous scaffold's interaction with rat cardiac cells, finding cardiomyocytes envelop fibers on all sides, while fibroblasts only touch one side. This study contributes to heart tissue regeneration and regenerative medicine.
Researchers discovered that most new cardiomyocytes come from cardiac progenitor cells during early embryonic development, but this ability fades as mice mature. The study's findings could lead to methods for regenerating heart tissue after a heart attack.
Researchers have mapped detailed molecular events underlying the transformation of ordinary fibroblast cells into therapeutic cardiac muscle cells. The study reveals key changes in protein levels, including a sharp rise in Agrin, which promotes repair processes and inhibits organ size regulation.
Researchers at the University of Pennsylvania have developed an injectable gel that slowly releases microRNAs to stimulate heart muscle regeneration. The gel's unique properties allow it to target specific signaling pathways related to cell proliferation, resulting in improved recovery rates and potentially life-prolonging effects.
Researchers at the University of Freiburg discover that DNA folding reorganization is a key switch for defining cell types during cardiomyocyte differentiation. The study reveals that spatial genome organization determines cellular identity and provides insights into future reprogramming strategies.
Researchers at UAB discovered that overexpressing a cell-cycle activator gene CCND2 increases the proliferation of grafted cardiomyocytes, leading to improved cardiac function and reduced infarct size. This breakthrough may pave the way for future clinical treatment of human heart attack patients.
Scientists at UNC School of Medicine compare two reprogramming techniques to generate patient-specific cardiomyocytes, finding that one method produces cells with embryonic cell signatures while the other yields cells with adult characteristics. This knowledge is crucial for developing new therapies and understanding cardiac disease.
A study published in Nature reveals a previously unknown connection between pathways that prevent heart cell renewal. The discovery opens the possibility of developing strategies to promote heart cell growth and regeneration. This finding may also lead to improved cardiac function in children with muscular dystrophy.
Researchers at Osaka University found that the immune system promotes spontaneous heart regeneration after myocarditis. Cardiomyocytes can proliferate under specific conditions, such as inflammation, and this process is mediated by factors like STAT3 and interleukin 11.
Researchers investigated Bax protein expression and myocardial changes in rabbits with acute left ventricle (LV) pressure overload. The study found that Bax protein expression decreased and morphological changes occurred, particularly on day 5 of the process.
Researchers studied cardiomyocyte autophagia in rabbits with acute focal ischemia. The study found that autophagy increases immediately after ischemia to protect cells, but decreases over time due to energy conservation. This mechanism helps prevent necrotic area expansion and cardiac death.
Researchers at the University of Cincinnati are developing a cell therapy that utilizes modified facial muscle cells to regenerate heart tissue. This innovative approach aims to address the limitations of existing treatments, which often rely on drug therapies or surgery, and may reduce rejection risks.
Cardiac diseases cause pathological growth leading to heart failure. Researchers found epigenetic marks responsible for this growth are lost in disease, allowing cells to switch back to fetal form and leading to irregular rhythms. This finding points to a new strategy for epigenetic therapy.
A study by researchers at Stanford University School of Medicine found that progressively shortening telomeres in heart muscle cells triggered a DNA damage response compromising mitochondrial function. This led to cardiomyopathy and death in mice with Duchenne muscular dystrophy, suggesting new therapeutic targets.
Researchers have created a robotic mimic of a stingray that's powered and guided by light-sensitive rat heart cells, demonstrating a new method for building bio-inspired robots through tissue engineering. The robotic stingray can be controlled using pulses of light, with different frequencies used to control its speed.
Researchers discovered that heart muscle cell chromosomes rapidly erode after birth, limiting their ability to proliferate and replace damaged heart tissue. Maintaining telomere length may boost regenerative capacity, improving cardiac tissue recovery after a heart attack.
Researchers have found a way to control heart muscle cells using laser radiation, which could lead to new treatments for arrhythmia. The study used azoTAB molecules and found that controlling the ion channels in cardiomyocytes can reduce abnormal heart rhythms.
A recent study published in the Journal of Cell Biology reveals that stem cell-derived cardiomyocytes have weaker contractile strength than their biological counterparts, which could explain shortcomings in clinical trials. The findings suggest that novel assays are needed to better understand the basic science behind stem cell therapy.
Researchers developed a muscle-on-a-chip model that demonstrates how cardiac stem cell therapies can fail due to inefficient force transmission between new and old heart cells. The study suggests that mechanical forces are not transmitted properly, leading to the formation of cellular adhesions that dissipate force to surrounding tissues.
A new study reveals that the β-1 adrenergic receptor and RAGE work together to cause myocardial injury and progression to cardiomyopathy. Blocking RAGE signaling after β-adrenergic agonist-induced heart failure mitigates cell death and restores cardiac function.
Researchers have shown that electrical stimulation of human heart muscle cells can aid their development and function. The team used electrical signals designed to mimic those in a developing heart to regulate and synchronize the beating properties of nascent cardiomyocytes, which support the beating function of the heart.
Researchers have developed a new technology that uses synthetic microRNA switches to purify live human cells with improved efficiency. The method, which involves identifying unique miRNAs for each cell type, shows promise for clinical applications and could lead to more homogeneous cell pools and better cell therapy outcomes.
Scientists at the Weizmann Institute of Science have successfully regenerated heart cells in adult mice using a previously unknown signaling pathway. By activating ERBB2, a protein that plays a role in heart development, researchers were able to induce cardiac cell renewal and regeneration without excessive growth or scarring.
Researchers at the University of Pennsylvania have discovered a way to reactivate cardiac muscle cell proliferation in adult hearts, leading to reduced scar formation and improved heart function after injury. The approach involves using synthetic microRNAs with short half-lives to induce cardiomyocyte growth.
A new study challenges the use of stem cells in heart attack patients, finding that they do not regenerate damaged heart tissue at high enough rates. The study suggests that any potential benefit from injecting c-kit-positive cells into the hearts of patients may come from improving circulation rather than generating new cardiomyocytes.
New research by UT Southwestern Medical Center discovered that high levels of oxygen in the postnatal environment result in cell cycle arrest of cardiomyocytes, making it impossible for adult hearts to regenerate. The study's findings have significant implications for cardiovascular medicine and may lead to new therapeutic approaches.